GPH Stock Chart & Stats
€2.74
€0.00(0.00%)
At close: 4:00 PM EDT
€2.74
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.74 - €2.74
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€4.29M
Enterprise Value-€11.64
Total Cash (Recent Filing)€15.45M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.49
Next Earnings
May 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.00
Shares Outstanding8,262,953
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)0.00
P/FCF Ratio-0.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.35
Revenue Forecast (FY)€4.96M
Bulls Say, Bears Say
Bulls Say
Aramchol ODF Increases CNS ExposureThe orally dispersible film (ODF) formulation materially raises systemic and CNS exposure and solves dysphagia in Parkinson’s patients. This durable improvement to delivery and adherence strengthens Aramchol’s positioning as a disease‑modifying CNS asset and enhances out‑licensing or co‑development appeal in a large market.
Cardiac‑targeted Aramchol LNP PlatformA cardiac‑targeted LNP formulation and AI‑enabled in vivo screening broaden Aramchol’s addressable indications into cardiac fibrosis. This platform diversification creates durable competitive optionality, supports higher‑value therapeutic claims, and makes the program more attractive for strategic partnerships and regulatory development pathways.
Minimal Financial LeverageEffectively no debt lowers bankruptcy and interest‑coverage risk and preserves strategic flexibility to fund R&D, acquisitions, or commercialization. For a development‑stage biotech, low leverage is a durable balance‑sheet strength that reduces financing constraints compared with highly leveraged peers.
Bears Say
No Product RevenueGalmed remains purely development‑stage with no revenue stream; reliance on pipeline milestones or asset monetization is persistent. Sustained net losses, which widened again in 2025 and TTM, mean the firm cannot self‑fund operations long term without external capital or successful commercialization/licensing.
Consistent Negative Operating And Free Cash FlowOperating and free cash flow have been negative each period; although burn improved from early years it worsened in the TTM. Persistent cash burn forces dependence on equity/debt raises, earnouts or partnerships, constraining strategic options and risking dilution unless revenue or licensing materializes.
Colospan Deal Adds Integration And Contingent CostsThe Colospan acquisition and €/$6M committed European expansion increase near‑term cash demands and add earnout contingencies. Colospan’s prior going‑concern notes and the contingent earnout raise execution and capital‑allocation risk, complicating Galmed’s already tight liquidity and strategic focus.
Galmed Pharmaceuticals News
GPH FAQ
What was Galmed Pharmaceuticals’s price range in the past 12 months?
Galmed Pharmaceuticals lowest stock price was €2.74 and its highest was €2.74 in the past 12 months.
What is Galmed Pharmaceuticals’s market cap?
Galmed Pharmaceuticals’s market cap is €4.29M.
When is Galmed Pharmaceuticals’s upcoming earnings report date?
Galmed Pharmaceuticals’s upcoming earnings report date is May 19, 2027 which is in 291 days.
How were Galmed Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Galmed Pharmaceuticals overvalued?
According to Wall Street analysts Galmed Pharmaceuticals’s price is currently Overvalued.
Does Galmed Pharmaceuticals pay dividends?
Galmed Pharmaceuticals does not currently pay dividends.
What is Galmed Pharmaceuticals’s EPS estimate?
Galmed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galmed Pharmaceuticals have?
Galmed Pharmaceuticals has 8,262,953 shares outstanding.
What happened to Galmed Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Galmed Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:GPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
GPH Stock 12 Month Forecast
Average Price Target
―Technical Analysis
AIM ImmunoTech
―
Jaguar Animal Health
―
Quoin Pharmaceuticals
―
Silo Pharma
―
Calidi Biotherapeutics
―